Skip to main content
Premium Trial:

Request an Annual Quote

Biocartis Nets $41M in Financing for IVD Development, Launch

NEW YORK (GenomeWeb News) – Swiss molecular diagnostics firm Biocartis said today that it has raised €30 million ($40.5 million) in a Series E equity financing.

The company plans to use the new capital to validate its Idylla platform and to continue developing a range of assays, most of them oncology-related.

Biocartis plans to launch the Idylla, a scalable biomarker-based in vitro diagnostic platform that does not require a lab environment or trained technicians, and its BRAF cancer assay, in the second half of 2014.

The investors in this financing round include existing shareholders such as RMM; Debiopharm Diagnostics; PMV Tina Fund; Johnson and Johnson Development Corporation; Philips; the Wellcome Trust; Petercam; Paul Janssen; Luc Verelst; Biocartis Founder Rudi Pauwels; and some smaller shareholders and company employees.

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.